A Japanese company focused on the production, purchase, and sale of pharmaceuticals and diagnostic reagents. Ono has developed and marketed drugs in multiple therapy areas including oncology, diabetes ...

Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration agreement with Reborna Biosciences Inc. to generate RNA-targeting novel small molecules in the field of the central nervous ...

Cue Biopharma, Inc. CUE shares are trading lower on Tuesday. The company reported 2024 fiscal-year earnings on Monday after ...

1 Day 4528 0.09% DJIA 0.01% S&P 500 0.16% Health Care/Life Sciences 0.63% ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

With the CSF-1R inhibitor space heating up, Germany's Merck Group has gone all-in on pimicotinib, paying Abbisko Therapeutics ...

At close: March 28 at 3:39:36 PM EDT ...

Research and development expenses were $36.3 million and $40.8 million for the years ended December 31, 2024 and 2023, respectively. The decrease was primarily due to decreases in clinical trial costs ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Ono Pharmaceutical has claimed FDA approval for Romvimza as a treatment for tenosynovial giant cell tumour (TGCT), setting up a market tussle with Daiichi Sankyo. CSF-1R inhibitor Romvimza ...